Keros Therapeutics, Inc. KROS
- elritercept — Myelodysplastic Syndromes Phase 3
- elritercept — Myelofibrosis Phase 3
- KER-206 Preclinical
GDF11 (1 companies · 3 programs)
Companies with an active program directed at GDF11.
Companies with an active program directed at GDF11.